Future studies will be directed to evaluate the therapeutic efficacy of chimeric mAb5E6 in combination with standard-of-care therapies and elucidate the impact of MUC16 targeting in the context of the tumor microenvironment. This evidence concerns the gene MUC16 and neoplasm.